deltatrials
Terminated PHASE2 INTERVENTIONAL 1-arm NCT03810105

A Study of Olaparib and Durvalumab in Prostate Cancer

A Phase II Study of Olaparib and Durvalumab in Men With Castration Sensitive Biochemically Recurrent Non-Metastatic Prostate Cancer Harboring Mutations in DNA Damage Repair

Sponsor: Memorial Sloan Kettering Cancer Center

Conditions Prostate Cancer
Interventions Durvalumab Olaparib
Updated 20 times since 2019 Last updated: Mar 11, 2024 Started: Mar 7, 2019 Primary completion: Jul 6, 2023 Completion: Jul 6, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Due to low accrual

Other terminated trials from Memorial Sloan Kettering Cancer Center

See all terminations from Memorial Sloan Kettering Cancer Center

Other Prostate Cancer trials with similar outcome

Browse all Prostate Cancer trials

This PHASE2 trial investigates Prostate Cancer and is currently terminated or withdrawn. Memorial Sloan Kettering Cancer Center leads this study, which shows 20 recorded versions since 2019 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Feb 2019 – ~Apr 2019 · 59 days · monthly snapshot~Apr 2019 – ~Jun 2019 · 2 months · monthly snapshot~Jun 2019 – ~Nov 2019 · 5 months · monthly snapshot~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~Jun 2020 · 6 months · monthly snapshot~Jun 2020 – ~Aug 2020 · 2 months · monthly snapshot~Aug 2020 – ~Oct 2020 · 2 months · monthly snapshot~Oct 2020 – ~Nov 2020 · 31 days · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Jun 2021 · 4 months · monthly snapshot~Jun 2021 – ~Oct 2021 · 4 months · monthly snapshot~Oct 2021 – ~Apr 2022 · 6 months · monthly snapshot~Apr 2022 – ~May 2023 · 13 months · monthly snapshot~May 2023 – ~Aug 2023 · 3 months · monthly snapshot~Aug 2023 – ~Mar 2024 · 7 months · monthly snapshot~Mar 2024 – ~May 2024 · 2 months · monthly snapshot~May 2024 – ~Jul 2024 · 2 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 24 months · monthly snapshot

Change History

20 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. May 2024 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Mar 2024 — May 2024 [monthly]

    Terminated PHASE2

    Status: Completed → Terminated

  5. Aug 2023 — Mar 2024 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

▶ Show 15 earlier versions

  1. May 2023 — Aug 2023 [monthly]

    Active Not Recruiting PHASE2

  2. Apr 2022 — May 2023 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  3. Oct 2021 — Apr 2022 [monthly]

    Recruiting PHASE2

  4. Jun 2021 — Oct 2021 [monthly]

    Recruiting PHASE2

  5. Feb 2021 — Jun 2021 [monthly]

    Recruiting PHASE2

  6. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE2

  7. Nov 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  8. Oct 2020 — Nov 2020 [monthly]

    Recruiting PHASE2

  9. Aug 2020 — Oct 2020 [monthly]

    Recruiting PHASE2

  10. Jun 2020 — Aug 2020 [monthly]

    Recruiting PHASE2

  11. Dec 2019 — Jun 2020 [monthly]

    Recruiting PHASE2

  12. Nov 2019 — Dec 2019 [monthly]

    Recruiting PHASE2

  13. Jun 2019 — Nov 2019 [monthly]

    Recruiting PHASE2

  14. Apr 2019 — Jun 2019 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  15. Feb 2019 — Apr 2019 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Memorial Sloan Kettering Cancer Center
Data source: Memorial Sloan Kettering Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations